9 Chong Kun Dang drugs hit with production, sale, prescription ban
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The Ministry of Food and Drug Safety is prohibiting pharmaceutical company Chong Kun Dang from selling and manufacturing some of its drugs for an indefinite period of time for adding substances to the products without approval from the regulatory agency.
The ministry said on Wednesday that the drug maker changed pharmaceutical additives for nine drugs at its own discretion and omitted manufacturing documents to conceal the alteration.
Drug companies are required to report to the agency when they change substances in the drugs.
The banned products include Pregrel, Depas, Bezalip, Uritos, Neo Cande Plus, Tamunal Cap and Time-R Cap.
The regulator has ordered health professionals not to prescribe the problematic medicines and is prohibiting the production and sale of them.
It will recall the drugs that are already in the market, although three of them – Bezalip, Uritos and Depas – will be exempt from the immediate recall considering patient need.
Still, the trio will be subject to the suspension in sale and production.
The ministry formed an inspection team of 18 this month to randomly inspect drug makers to see if production is done in accordance with rules.
The team cracked down on four makers including Chong Kun Dang, but three others were found to have abided by the safety regulations.
BY PARK EUN-JEE [park.eunjee@joongang.co.kr]
Copyright © 코리아중앙데일리. 무단전재 및 재배포 금지.